Sinovac Biotech Ltd
NASDAQ: SVA · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-06-05
Sinovac Biotech Ltd (SVA) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-1.54M | $-1.13M | $-1.64M | $4.32M | $10.50M | $48.41M | $-14.28M | $13.94M | $-16.25M | $5.58M | $-10.13M | $4.21M | $-15.46M | $59.76M | $7.94M | $39.07M | $479.31M | $15.35B | $-770.75M | $106.02M |
| Capital expenditures | $1.65M | $1.65M | $1.14M | $2.47M | $3.98M | $4.32M | $25.38M | $15.46M | $16.16M | $5.13M | $10.91M | $5.30M | $12.65M | $11.91M | $5.61M | $10.63M | $127.65M | $719.98M | $403.37M | $145.69M |
| Depreciation | $899185.00 | $899185.00 | $1.27M | $1.40M | $1.77M | $2.24M | $4.23M | $4.83M | $4.49M | $6.41M | $8.10M | $6.52M | $5.31M | $4.88M | $5.14M | $4.82M | $4.04M | $86.83M | $156.60M | $144.75M |
| Stock-based comp | $439904.00 | — | $-132314.00 | $2.72M | $66542.00 | $422860.00 | $459901.00 | $206000.00 | $347000.00 | $281000.00 | $287000.00 | $952000.00 | $2.41M | $979000.00 | $4.30M | $3.00M | $10.20M | $7.74M | $149.49M | $0.00 |
| Free cash flow | $-3.19M | $-2.78M | $-2.78M | $1.85M | $6.53M | $44.09M | $-39.66M | $-1.52M | $-32.41M | $443000.00 | $-21.04M | $-1.09M | $-28.11M | $47.84M | $2.33M | $28.45M | $351.66M | $14.63B | $-1.17B | $-39.67M |
| Investing cash flow | $-3.05M | — | $-569318.00 | $-2.44M | $-3.96M | $-11.69M | $-19.24M | $-13.79M | $-16.15M | $-5.18M | $-11.00M | $-4.51M | $-11.78M | $-11.90M | $-25.26M | $-42.45M | $-204.76M | $-3.02B | $-5.76B | $-2.93B |
| Financing cash flow | $5.78M | $6.55M | $3.98M | $5.56M | $8.32M | $5.29M | $58.19M | $613000.00 | $17.33M | $14.42M | $5.31M | $-24.20M | $27.78M | $-1.34M | $64.18M | $1.74M | $592.57M | $-1.90B | $-241.40M | $-76.06M |
| Dividends paid | — | $379123.00 | $379123.00 | — | $2.95M | $3.85M | $3.29M | — | — | $649000.00 | $649000.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | $0.00 | $1.88B | $263.17M | $328.08M |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — | — | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — |
Frequently asked questions
What is Sinovac Biotech Ltd's revenue?
Sinovac Biotech Ltd's trailing twelve-month revenue is $510.62M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is SVA?
In its most recent fiscal year, SVA ran a gross margin of 59.51%, an operating margin of -121.96%, and a net margin of -22.29%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does SVA generate?
SVA produced $-39.67M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is SVA's balance sheet healthy?
SVA holds $1.27B in cash and equivalents against $177.82M in long-term debt, on $8.71B of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.